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Besides its crucial role in many physiological events, 17β-estradiol (E2) exerts protective
effects in the central nervous system. The E2 effects are not restricted to the brain areas
related with the control of reproductive function, but rather are widespread throughout
the developing and the adult brain. E2 actions are mediated through estrogen receptors
(i.e., ERα and ERβ) belonging to the nuclear receptor super-family. As members of the
ligand-regulated transcription factor family, classically, the actions of ERs in the brain were
thought to mediate only the E2 long-term transcriptional effects. However, a growing body
of evidence highlighted rapid, membrane initiated E2 effects in the brain that are indepen-
dent of ER transcriptional activities and are involved in E2-induced neuroprotection. The
aim of this review is to focus on the rapid effects of E2 in the brain highlighting the speciﬁc
role of the signaling pathway(s) of the ERβ subtype in the neuroprotective actions of E2.
Keywords: estrogen receptor α, estrogen receptor β, 17β-estradiol, neuroprotective effects, membrane initiated
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INTRODUCTION
Inwomen at approximately 51 years of age starts a profoundphysi-
ological change known as menopause, which is accompanied with
a dramatic decrease in estrogen levels. Taking into the account
that the average of life span has increased from 50 years to over
80 years of age, an increasing number of women are living a larger
portion of their lives in a chronically hypo-estrogenic state (Wise
et al., 2001). The post-menopausal state of estrogen deﬁciency
leads to different consequences throughout the female body which
include the increased risk for osteoporosis and cardiovascular dis-
eases (McEwen, 2002; Gillies and McArthur, 2010). Besides these
effects, most studies have recognized that the brain is one of the
organs of the body that suffer estrogen deﬁciency.
In addition to the well-established effects of estrogens on the
reproductive behaviors and the associated brain regions (e.g.,
hypothalamus), 17β-estradiol (E2), the most active estrogen, also
serves as a neurotrophic and a neuroprotective agent. Indeed, E2
inﬂuences memory formation, cognition, mood, pain sensitivity,
motor coordination, neurodevelopment, and neurodegeneration
(Wise et al., 2001; McEwen, 2002; Barha and Galea, 2010; Gillies
andMcArthur,2010). E2 elicits either organizational effects during
embryonic and neonatal development or the activational control
of gene expression during the later stages of life cycle by regulat-
ing synaptic transmission, neuronal survival, neuronal, and glial
differentiation (Garcia-Segura et al., 2001; Woolley, 2007; Don-
Carlos et al., 2009). In addition, different experimental models of
neurodegeneration have shown that E2 acts as a neuroprotective
factor promoting neuronal survival and tissue integrity (Maggi
et al., 2004; Suzuki et al., 2006; Marin et al., 2009).
Most of these actions of E2 are mediated by estrogen recep-
tors (i.e., ERα and ERβ) belonging to the nuclear receptor
super-family (Pettersson and Gustafsson, 2001; Ascenzi et al.,
2006).Asmembers of ligand-regulated transcription factor family,
classically, ERs were thought to mediate only the E2 long-term
transcriptional effects. However, a growing body of evidence high-
lighted rapid, membrane initiated E2 effects that are independent
of the ER transcriptional control (Raz et al., 2008; Arnold and
Beyer, 2009; De Marinis et al., 2011; Roepke et al., 2011).
Although different subtypes of ER have been reported on neu-
ronal membranes, emerging pharmacological and ultra-structural
evidences demonstrated that ERα and ERβ are localized at the cell
membrane where mediate rapid activation of intracellular brain
signaling pathways (Vasudevan and Pfaff, 2007; Raz et al., 2008;
De Marinis et al., 2010; Gillies and McArthur, 2010).
This review will highlights the rapid effects of E2 in the brain
taking into account the contribution of ERβ intracellular signaling
pathway in neuroprotective actions of E2.
STRUCTURE AND ACTIVITY OF ESTROGEN RECEPTORS
Estrogen receptor alpha and ERβ (NR3A1 and NR3A2, respec-
tively) are products of separate genes (ESR1 and ESR2, respec-
tively) present on distinct chromosomes (locus 6q25.1 and locus
14q23-24.1, respectively; Gosden et al., 1986; Ascenzi et al., 2006;
Luisi et al., 2006; Zhou et al., 2006).
Like other members of the NR family, ERs contain evolution-
arily conserved structurally and functionally distinct domains.
In particular, ERs are modular proteins composed of six regions
named A/B, C, D, E, and F which participate in the formation of
independent but interacting functional domains. DNA-binding
domain (DBD or C region), the central and most conserved
domain, plays a pivotal role in receptor dimerization and in
the binding of speciﬁc DNA consensus sequences (i.e., estrogen
responsive elements, EREs) recognized by both receptors, whereas
ligand binding occurs in the C-terminal multifunctional ligand
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binding domain (LBD or E region; Ascenzi et al., 2006). ERs
transcriptional activation ismediated by twodistinct transcription
activation functions (AFs). The AF-1 is located at the N-terminus
of the receptor and the AF-2 domain resides in the LBD (Ascenzi
et al., 2006; Acconcia and Marino, 2011).
Classically, the ER biological activities result from modiﬁca-
tions of the expression pattern of speciﬁc target genes. In the
absence of ligands, ERs cycle on and off their DNA-binding sites
(i.e., EREs). The trans-activation activity of ERs initiates after the
binding of E2 which stabilizes the binding of receptors to DNA
(Metivier et al., 2003; Reid et al., 2003; Picard et al., 2008; Acconcia
and Marino, 2011).
In the cytoplasm of the ER-expressing cells, ER is in the
monomeric state (inactive state) and forms a multiprotein com-
plex with immunophilins and heat shock proteins (e.g., Hsp90,
Hsp70, and Hsp56). Upon E2 binding, Hsps dissociate from ERs
which dimerize and translocate to the nucleus. In the nucleus,
the E2:ER complexes interact with ERE sequences within the pro-
moter regions of target genes to regulate gene transcription by
recruiting cofactors proteins (i.e., coactivators and corepressors)
and the components of the transcriptionmachinery (Ascenzi et al.,
2006; Acconcia and Marino, 2011). Thus, the ER-macromolecular
complexes facilitate the transcriptional activities of E2 respon-
sive genes by triggering chromatin remodeling in target promoters
(Ascenzi et al., 2006; Morissette et al., 2008; Acconcia and Marino,
2011).
The consensus palindromic element ERE, 5′-GGTCAnnnTG
ACC-3′, acts in a direction and distance independent manner,
both of which are properties of an enhancer (Ascenzi et al., 2006).
Nevertheless, only a fraction of known mammalian ERE dis-
plays this consensus, about one-third of the ER-regulated genes
in humans do not contain ERE-like sequences (O’Lone et al.,
2004; Bjornstrom and Sjoberg, 2005). Indeed, ERs can also reg-
ulate gene transcription without binding directly to DNA. This
indirect genomic mechanism requires the interaction of ERs with
eitherDNA-bound transcription factors likeCREBorwith Fos and
Jun proteins regulating gene transcription via the activator protein
1 (AP-1) and stimulating protein 1 (Sp1; Kalaitzidis and Gilmore,
2005; Morissette et al., 2008; Acconcia and Marino, 2011).
Since 1967 it has been reported that E2 induces rapid effects in
target cells that can not be related to ER transcriptional activities
(Szego and Davis, 1967). Rapid effects of E2 have been reported
in bone, breast, blood vessels, cancer cells, nervous system, sperm,
and maturating oocytes (Nilsson and Gustafsson, 2011). E2 rapid
induce the activation of several intracellular pathways (Kelly and
Levin,2001; Levin,2005;Ascenzi et al., 2006;Acconcia andMarino,
2011). E2-induced rapid responses are important for several neural
functions including cognition, behavior, stress responses, and
reproduction (Farach-Carson and Davis, 2003).
E2 membrane initiated actions require ER localization at the
plasmamembrane. Membrane ERs are localized either in caveolae
(Razandi et al., 2003) or in other membrane raft structures (Mar-
quez et al., 2006; Acconcia and Marino, 2011). Remarkably, ERα
and ERβ can be localized at the plasma membrane through the
direct interaction with caveolin-1 to initiate the signal transduc-
tion pathway(s) (Acconcia andMarino, 2011; Roepke et al., 2011).
Indeed, ERs require a post translational modiﬁcation by lipid (i.e.,
S-palmitoylation) to be localized at the plasma membrane, to
interact with caveolin-1, and to initiate the E2 rapid signal cas-
cade activation (Acconcia et al., 2005;Galluzzo et al., 2007; Pedram
et al., 2007; Marino and Ascenzi, 2008).
In addition, E2 determines rapid membrane initiated effects
through other receptors belonging to a protein family completely
different from nuclear receptor super-family. This class of recep-
tors includesER-XandaG-protein coupled seven-transmembrane
receptor, named GPR30 (Toran-Allerand et al., 2002; Filardo
et al., 2007). ER-X is oriented in caveolar-like microdomains of
postnatal, but not adult, mouse neocortical, and uterine plasma
membrane. It is functionally distinct from ERα and ERβ, and is
re-expressed in the adult brain after ischemic stroke injury, like
ERα (Toran-Allerand et al., 2002). GPR30 is expressed in areas of
the brain important for spatial learning, memory, and attention
and could be an important regulator of basal forebrain choliner-
gic functions (Prossnitz and Barton, 2011). In vivo studies showed
that only pharmacological concentrations of the GPR30 speciﬁc
ligand G-1 (i.e., 50μg) could replicate the effects of the physi-
ological concentration of E2 (i.e., 2.2μg) in promoting neuronal
survival following global ischemia in the rodent brain (Etgen et al.,
2011). Although GPR30 and its ligand may represent a new phar-
macological approach for treating neuronal damage, the role of
these receptors in cells from ERα/ERβ homozygous double knock-
out (DERKO) mice is not yet demonstrated; thus, at present,
the possibility that GPR30 and/or ER-X mediate the E2-induced
rapid transduction pathways important for brain functions is
questionable.
In addition, membrane ERs activate rapid transduction path-
way(s) by interacting with either cell surface receptors, such as
the growth factor receptors (e.g., the EGF receptor and the IGF-1
receptor) and the metabotropic glutamate receptor, or with other
signal proteins including G-proteins, non-growth factor tyrosine
kinase (e.g., Src and Ras), and linker proteins (e.g., MNAR and
striatin; Hammes and Levin, 2007; Gillies and McArthur, 2010).
In Figure 1 a schematic representation of nuclear and extranuclear
ER activities is reported.
ESTROGEN EFFECTS AND ACTION MECHANISMS IN THE
BRAIN
E2 in the brain is either locally synthesized by the precursor
testosterone or imported through the blood brain barrier from
circulating factors. ERs are expressed in different brain regions
such as the bed nucleus of the stria terminalis, the medial amyg-
dala, the preoptic area, and the nucleus of the solitary tract. ERα is
predominantly located in the hypothalamus ventromedial nucleus
and in the amygdala of humans and rodents (Shughrue et al.,
1998; Osterlund et al., 2000a,b,c; Gillies and McArthur, 2010).
On the contrary, ERβ is the predominant form expressed in the
cerebral cortex, the hippocampus, the dorsal raphe, the substantia
nigra, the cerebellum, and the hypothalamic nuclei; also seroton-
ergic and dopaminergic neurons express ERβ (Bodo and Rissman,
2006; Handa et al., 2010). In the mammalian nervous system,
ERα and ERβ distribution patterns provide some neuroanatom-
ical evidences for their involvement in speciﬁc brain functions.
Indeed, ERα, but not ERβ, is crucial for E2-induced neurore-
productive functions (Ogawa et al., 1998), however many of the
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FIGURE 1 | Schematic model illustrating the relationship between
extranuclear and nuclear actions of E2 on target cells. E2, 17β-estradiol;
mER, estrogen receptor located at the plasma membrane; ER, estrogen
receptor; AP-1, activating factor-1. For details, see text.
non-reproductive functions of E2 in the brain can be explained
only throughERβ-mediated effects (Kudwa et al., 2006;Antal et al.,
2008).
Although E2 is the predominant circulating sex steroid hor-
mone after puberty in females, it also plays a pivotal role in the
male brain, E2 being synthesized from steroid precursors (e.g.,
testosterone by P450 aromatase enzyme). Testosterone produced
during the critical developmental window in male is a key fac-
tor in the masculinization/defeminization process (Huhtaniemi,
1994). Morphological, cellular, and molecular differences exist in
diversemale and female brain regions important for cognition and
memory (e.g., the hippocampus, the amygdala, the cortex, and the
regions controlling sensorimotor and reward systems; see Gillies
and McArthur, 2010).
Functional differences in male and female brain explain the
diverse responses to environmental challenges and different vul-
nerabilities to behavioral and neurological disorders. Striking dif-
ferences between sexes have been reported concerning the symp-
toms, the prevalence, the progression, and the severity of several
neurodegenerative diseases. Indeed,pre-menopausal women seem
to be less prone to Alzheimer’s, Parkinson’s, and Huntington’s
diseases than males or post-menopausal women (Amantea et al.,
2005; Morissette et al., 2008 and literature cited therein). More-
over, the pivotal role of E2 on higher brain functions including
mood, anxiety, fear, learning, andmemory have been conﬁrmed by
epidemiological data which indicate that pre-menopausal women
seem to be more vulnerable that men to develop anxiety or
depression behavior (Schneier et al., 1992; Kessler et al., 1994;
Breslau et al., 1995; Seeman, 1997; Luine, 2008; Watson et al.,
2010).
E2 AS A NEUROTROPHIC FACTOR
E2 exerts multiple and diverse actions in the brain throughout
the life span from development to senescence. E2 exerts neu-
rotrophic and neuroprotective effect in adult brain regulating the
synthesis and the secretory patterns of neurotransmitters, neu-
ropeptides, and their receptors, inﬂuencing the sexual behavior as
well as gonadotropin and prolactin secretion (Pfaff et al., 1994).
Moreover, as it does during development.
E2 is a potent trophic factor that inﬂuences brain development
and differentiation, plasticity and cell survival both during fetal
life and in the early postnatal period. These trophic effects include
the modulation of cell migration, neuronal growth, formation,
and elimination of synapses, and neurogenesis (Pfaff et al., 1994;
Garcia-Segura et al., 1996;Wise et al., 2001; Gillies and McArthur,
2010).
In nearly all mammalian species, including humans, adult neu-
rogenesis has been observed in two brain regions characterized
by neuronal progenitor cells (NPCs): the dentate gyrus of the
hippocampus and the lateral walls of lateral ventricles (Gould
et al., 1997, 2001; Eriksson et al., 1998; Amrein et al., 2004; Handa
et al., 2010). E2 can promote the proliferation of hippocampal
neuron progenitor cells in vitro and neurogenesis in rat hippocam-
pus in vivo, both under physiological and pathological conditions
(Tanapat et al., 1999, 2005; Brannvall et al., 2002, 2005; Suzuki
et al., 2007). In human NPCs, E2-induced proliferation seems to
be mediated only by ERβ (Wang et al., 2008), which represent the
predominant ER subtype in these cells (Fried et al., 2004; Hong
et al., 2004). Interestingly, both E2 and the ERβ selective-ligand
diarylpropionitrile (DPN) are able to induce in vitro humanNPCs
proliferation through the activation of ERβ that in turn leads to a
rapid increase in kinase levels (Squires et al., 2002; Ussar andVoss,
2004; Hata et al., 2005; Chambard et al., 2007; Wang et al., 2008;
Handa et al., 2010).
Neurogenesis is involved in hippocampus-dependent learning
andmemory, it is highly correlatedwith the chronic antidepressant
treatment of male and female rodents affected by the depressive-
like behavior; the antidepressant treatment increases also cell pro-
liferation (Malberg andDuman, 2003;Vollmayr et al., 2003; Green
and Galea, 2008). Moreover, neurogenesis could represent a neu-
roprotective action of E2 in neurodegenerative conditions such as
Alzheimer’s disease,which is accompanied by a decline of neuroge-
nesis (Wang et al., 2007, 2010; Rodriguez et al., 2008; Demars et al.,
2010). In addition to the reported effects, E2 in the hippocam-
pus enhances learning and memory promoting the formation of
new dendritic spines and new excitatory synapses, increasing the
expression of NMDA receptors (Adams et al., 2004), and enhanc-
ing long-term potentiation (LTP; Smith and McMahon, 2006; Liu
et al., 2008).
Dramatic changes in E2 levels, due to surgery and/or to
menopause, are associated with changes in incidence and symp-
tomatology of anxiety and depression, in memory ability, and
performance in visual–spatial tasks (Hampson and Kimura, 1988;
Phillips and Sherwin, 1992). E2 replacement can improve mood
score (Wise et al., 2001; Walf and Frye, 2006) and counteract
memory loss inboth verbal andnon-verbalmemory test and atten-
tion (Campbell and Whitehead, 1977; Halbreich, 1997; Rhodes
and Frye, 2004; Sherwin, 2005). Further conﬁrmation of the
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E2 involvement in higher brain functions derives from animal
models. In fact, an increased anxiety-related behavior has been
observed in both rats and mice as a consequence of E2 decline
levels (Gupta et al., 2001; Morgan and Pfaff, 2001, 2002; Bodo and
Rissman, 2006; Inagaki et al., 2010; Jacome et al., 2010).
MECHANISMS UNDERLYING E2-INDUCED EFFECTS ON
NEUROTROPHISM
The hippocampus seems to represent the main brain area that
mediate E2 effects on the affective behavior and the cognitive func-
tion. Together with the amygdala area, hippocampus is considered
an important component of the limbic system and a regula-
tor of the hypothalamic–pituitary–adrenal axis (HPA; Walf and
Frye, 2006). Although the proper mechanism by which E2 acts
in hippocampus is openly debated, growing evidence indicates
that E2 effects are rapid and could require a membrane-associated
receptor (Walf and Frye, 2007, 2008).
Although rapid membrane-mediated effects of E2 have been
identiﬁed in the hippocampus and in some hypothalamic nuclei
(Ronnekleiv and Kelly, 2005; Roepke et al., 2009), they may occur
throughout the whole central nervous system. Membrane initi-
ated E2 signaling involves the rapid activation of various pro-
tein kinase cascades, including protein kinase C (PKC), protein
kinase A (PKA), phosphatidylinositol-3 kinase (PI3K), protein
kinase B (or Akt), and mitogen-activated protein kinase (MAPK),
which in turn modulate protein phosphorylation, cation channel
activity, and gene expression (Roepke et al., 2011). Furthermore,
E2-activated signaling pathways modulate the intracellular Ca2+
levels regulating the activation of protein kinases including the
Ca2+-calmodulin-dependent protein kinase II (CaMKII; Gillies
and McArthur, 2010).
A rapid induction of the cAMP/PKA pathway, mediating the
effect of E2 on the change of K+ ﬂuxes in GnRH neurons (Gu
and Moss, 1996; Malyala et al., 2005), has been demonstrated in
hippocampal neurons (Chen et al., 1998; Ascenzi et al., 2006).
Moreover, E2 can attenuate the ability of μ-opioid and GABA
receptor-mediated activation of G-protein-gated inwardly recti-
fying K+ channels (Kelly et al., 1992). Notably, PKA is involved
in this E2-induced pathway, in fact forskolin, a PKA activator,
and cAMP can mimic the E2 effects (Lagrange et al., 1997). Sev-
eral in vitro reports, using hippocampal primary cell culture,
have demonstrated that E2 can activate intracellular signaling
pathway(s) to indirectly affect the genomic activity through tran-
scriptional regulators such as the cAMP response element binding
protein (CREBP; Kelly and Levin, 2001; Wade and Dorsa, 2003;
Lee et al., 2004). Notably, CREBP is regulated through phospho-
rylation by several signaling kinases, including Akt, CaMKII, and
MAPK (Brunet et al., 2001; Sawai et al., 2002). The E2-dependent
phosphorylation of CREBP has been shown to be a critical step in
neuronal survival, synaptic plasticity, and learning as well as par-
ticularly in processes that lead to the“generation”of new dendritic
spines in dissociated hippocampal neurons (Murphy and Segal,
1996, 1997).
The regulation of AMPA receptors is a key mechanism for the
potentiation of synaptic strength in LTP, which is considered a cel-
lularmodel of learning andmemory (Bliss andCollingridge, 1993;
Malinow andMalenka, 2002;Malenka and Bear, 2004). Treatment
of hippocampal slices with the ERβ agonist WAY-200070 induces
a PKA-dependent phosphorylation of the GLUR1 subunit, which
leads to the increased expression of AMPAR at the cell surface.
Furthermore, ERβ activation induces morphological changes in
hippocampal neurons in vivo, including increased branching and
density of spines (Liu et al., 2008).
E2 AS A NEUROPROTECTIVE AGENT
E2plays a signiﬁcantneuroprotective role in thebrain, this explains
its ability to ameliorate symptoms and to decrease the risk of
neurodegenerative events and of ischemic stroke, Alzheimer’s,
Parkinson’s, and Huntington’s diseases (Amantea et al., 2005). In
particular,E2 displays neuroprotection againstAβ amyloid toxicity
(Fitzpatrick et al., 2002; Guerra et al., 2004) and oxidative stress-
induced neuronal death (Bae et al., 2000; Wang et al., 2006; De
Marinis et al., 2010) in many neuronal cell lines and tissue prepa-
rations. Moreover, E2 seems to protect neurons against apoptosis
by reducing reactive oxygen species (ROS) production (Razmara
et al., 2007; Irwin et al., 2008; Numakawa et al., 2011), inhibiting
the neurotoxic effect of oxidized LDL and glutamate (Bhavnani,
2003), maintaining the Ca2+ homeostasis (Ba et al., 2004a), reg-
ulating pro-apoptotic caspase activities (Bao et al., 2011), and
maintaining mitochondrial membrane integrity (Simpkins and
Dykens, 2008; Arnold and Beyer, 2009; Wang et al., 2011). Fur-
thermore, E2 displays neuroprotection against ischemic injuries
(Dubal et al., 2001; Carswell et al., 2004). Remarkably, the inhibi-
tion of cell death by E2 has been demonstrated in neuronal cell
lines, such as NT2 neurons, PC12, mouse hippocampal T22 neu-
rons, as well as mouse and human neuroblastoma cells exposed to
glutamate, hydrogen peroxide, and AMPA (Zaulyanov et al., 1999;
Ba et al., 2004b; Sribnick et al., 2004; Amantea et al., 2005; De
Marinis et al., 2010).
Both nuclear and membrane initiated mechanisms of action
are required for the neuroprotective role of E2. ERs can interact
directly with the MAPK pathway resulting in the activation of a
wide variety of transcription factors involved in neuronal survival
(Morissette et al., 2008). Notably,MAPK signaling is accompanied
by the activation of CREBP, the induction of Bcl-2 expression,
and the inhibition of the apoptotic cascade (Azcoitia et al., 2011).
In particular, the E2 neuroprotective effects against the quinolonic
acid-induced toxicity in rat hippocampus cells is abolished by pre-
treatment with U0126, an inhibitor of MAPK/ERK kinase (Kuroki
et al., 2001).
Estrogen receptors can also interact with the PI3K signaling
pathway leading to activation of the effector protein kinase Akt.
Activated Akt, in turn, can modulate the expression of apopto-
sis inhibitors (i.e., Bcl-2 and Bcl-x) or inducers (i.e., Bax and
Bad), thus inﬂuencing cell death. Similarly, phosphorylation of
either caspase-9 or the fork head transcription factors by Akt
could further block the apoptosis induction in neurons. There-
fore, Akt promotes cell survival opposing to the apoptosis by a
variety of routes. In particular, the PI3K/Akt pathway is shown to
be a critical survival mechanism in the neuroprotective activities
of E2 in dopamine neurotransmission in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine mice model of Parkinson’s disease.
In this model, Akt activates anti-apoptotic proteins and inacti-
vates glycogen synthase kinase-3β (GSK3β) activity by increasing
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the phosphorylation level of Ser9 and Ser21. GSK3β is highly
expressed in the central nervous system; the activation of GSK3β
facilitates neuronal death whereas its inactivation promotes cellu-
lar mechanisms involved in neuronal survival pathways. Further-
more, evidence shows that GSK3β could play a key role in the
pathogenesis of the Alzheimer’s disease (Morissette et al., 2008).
E2 rapidly promotes the phosphorylation and the subsequent
inactivation of the voltage dependent anion channel (VDAC), a
mitochondrial porin also found at the neuronal membrane, where
it appears to be involved in redox regulation, extrinsic pathway,
and Aβ amyloid neurotoxicity. This E2 effect requires the activa-
tion of PKA and Src-kinase whichmay be relevant tomaintain this
channel inactivated (Herrera et al., 2011).
ERβ-SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN
E2-INDUCED NEUROPROTECTION
Whereas ERα is a critical link in themechanismof E2 neuroprotec-
tion, the role of ERβ is less clear. By now there is growing evidence
from in vitro and in vivo studies which shows the involvement of
ERβ-mediated rapid signaling in neuroprotection. Despite both
ERs are expressed by hippocampal neurons, E2 effects on hip-
pocampus seem to be mediated by ERβ which is more prevalent
than ERα (Shughrue et al., 1996, 1998; Laﬂamme et al., 1998;
Hileman et al., 1999; Mitra et al., 2003). Different studies, based
on knockout animal models, have been performed to determine
whetherERβ in thehippocampus is aE2 target.Notably,E2-treated
wild-type mice exhibit a less depressive-like behavior than con-
trols, this E2 effect is lost in ERβ knockout mice βERKO (Rocha
et al., 2005; Weiser et al., 2008). Furthermore, ovariectomized
female rats treated with the ERβ agonist DPN show a decrease
of the anxiety-type behavior (Weiser et al., 2009) and the admin-
istration of ERβ-selective ligands directly in the hippocampus
decreases the depressive-like behavior suggesting the pivotal role
of this brain area (Walf and Frye, 2007). All together, these results
indicate that the ERβ-mediated mechanism(s) is pivotal for the
E2-induced synaptic plasticity modulation in the hippocampus
and, ultimately, for E2-induced learning and memory.
Exposure of human SK-N-BE neuroblastoma cell to H2O2
(=50μM) induces the increase of ROS in cells (followed by oxi-
dation of proteins, lipids, and DNA), glutathione depletion, mito-
chondria dysfunction, intracellular Ca2+ increase, and caspase-3
activation followed by apoptotic cell death (Wang et al., 2006).
Recently, cells pre-treatment with physiological E2 concentration
has been demonstrated to decrease cell death and to reduce the
activation of the pro-apoptotic cascade (i.e., caspase-3 activation
and PARP cleavage; De Marinis et al., 2010).
Although SK-N-BE cells express different level of both ER
subtypes, the E2-protective effects against H2O2-induced neuron
toxicity required rapid ERβ-activities (De Marinis et al., 2010). In
fact, cell pre-treatment with the speciﬁc ERβ-inhibitor THC com-
pletely prevents E2 effects (De Marinis et al., 2010). Interestingly,
the monomeric globin neuroglobin (Ngb), displaying a protective
function in the brain (Fago et al., 2008; Burmester and Hankeln,
2009; Yu et al., 2009; De Marinis et al., 2010, 2011; DellaValle
et al., 2010), is pivotal in ERβ-mediated effects on neuroprotec-
tion (De Marinis et al., 2010). The E2 effect on Ngb expression
is rapid (1 h), persistent (24 h), speciﬁc, and mediated by the ERβ
subtype. In particular, the E2-induction of Ngb increase requires
the ERβ-mediated rapid activation of p38/MAPK. Moreover, cell
pre-treatment with the transcription inhibitor actinomycin and
the translation inhibitor cycloheximide completely prevents the
increase of E2-induced Ngb levels. Note that the integration
between rapid and genomic ERβ-mediated events is required
to guarantee rapid and persistent E2 effects in neuroprotection
against H2O2 toxicity (De Marinis et al., 2010). Furthermore,
in mouse primary cortical astrocytes, one of the cellular targets
of E2 in the brain (Arevalo et al., 2010), E2 stimulation reduces
lipopolysaccharide-induced cytokine production only in the pres-
ence of ERβ-induced increase of Ngb protein levels (Marino M.,
unpublished data).As awhole, these data suggest a newmembrane
initiated signaling pathway involving ERβ, p38/MAPK, and Ngb
in E2-induced neuroprotection (Figure 2).
However, conﬂicting data are available on the role played by
ERβ in neuroprotection. Several in vivo studies in ERα (αERKO)
and ERβ (βERKO) knockout mice model of cerebral ischemia
report the pivotal role of ERα, but not of ERβ, in themechanism(s)
associated with the estrogen-mediated neuroprotection in differ-
ent brain regions, such as the cortex and the striatum (Dubal et al.,
2001). Moreover, ERβ seems to be not involved in E2-induced
neuroprotection against the Aβ amyloid toxicity in septal-derived
SN56 cells and in hippocampal-derived cell line HT22 (Guerra
et al., 2004; Marin et al., 2007). On the other hand, a pronounced
FIGURE 2 | Schematic model illustrating the ERβ-dependent
E2-induced neuroprotection against oxidative stress. Exposure to
oxidative stress induces cytochrome c (cyt c) release into the cytoplasm.
Once in the cytosol cyt c mediates the activation of the adaptor molecule
apoptosis–protease activating factor-1 (Apaf-1), generating the apoptosome.
Apoptosome can recruit caspase-9 favoring proteinase activation. These
events induce the catalytic maturation of caspase-3, which mediates the
biochemical and morphological features of apoptosis. E2, via the synergy
between extranuclear and nuclear ERβ activities, increases neuroglobin
(Ngb) levels, reallocates Ngb at mitochondria, facilitates Ngb-cytochrome c
interaction, and prevents apoptosome formation. For details, see text.
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E2 neuroprotection against β-amyloid peptide in HT22 cells sta-
bly transfected with ERβ (HTERβ) and with ERα (HTERα) has
been reported. In particular, E2 induced a similar time course of
MAPK activation in ERα or ERβ expressing cells (maximal activa-
tion at 15min) which was necessary for neuroprotection against
β-amyloid toxicity (Fitzpatrick et al., 2002). Moreover, the loss
of ERα did not enhance tissue damage in the female mice after
experimental stroke (Sampei et al., 2000). Furthermore, Carswell
et al. (2004) showed that administration of the speciﬁc ERβ ago-
nist DPN reduced ischemic damage in the striatum and in the
CA1 region of the hippocampus in ovariectomized C57B1/6Jmice
while pre-treatment with the ERα agonist PPT had no effect on
the extension of the area affected by neural damage.
Further evidence for the involvement of ERβ-mediated effect(s)
in neuroprotection derives from studies on the Mongolian Gerbil
global cerebral ischemia model. In this in vivo model, it has been
demonstrated that the plant-derived phytoestrogen genistein, a
mild-selective agonist for ERβ (with more than sevenfold higher
binding afﬁnity for ERβ than ERα; Kuiper et al., 1997), reversed
ischemic-induced memory impairment, evaluated through both
behavior and object recognition tests, and fully promoted survival
of pyramidal cells in the CA1 hippocampal subﬁeld.Moreover, the
use of the selective ERβ antagonist PHTTP completely prevented
the neuroprotective effect(s) of genistein (Donzelli et al., 2010).
These ﬁndings conﬁrmed data obtained administrating genistein
before injury in focal cerebral ischemia in the mouse (Trieu et al.,
1999), and in global cerebral ischemia in rats (Schreihofer et al.,
2005) and gerbils (Kindy, 1993).
CONCLUSION
Inmammals, E2 exerts a profound inﬂuence onmultiple brain cir-
cuits involved in reproductive and non-reproductive physiology
and behavior. In fact, E2 modulates inﬂammatory processes, anxi-
ety, depressive-like behaviors, and cognitive functions. In addition,
an increasing number of evidence suggests that E2 exerts signiﬁ-
cant neuroprotective effects against a variety of neurodegenerative
pathologies such as the Alzheimer’s and Parkinson’s diseases.
Several studies based on both in vitro and in vivo models
demonstrated that E2 can exert its neuroprotective role against
multiple types of insults including Aβ-amyloid toxicity, ischemic
injuries, and other oxidative stresses. Furthermore, E2 acts in the
brain modulating synaptogenesis, neurogenesis, inﬂammation,
and protecting neurons against apoptosis.
In addition to the well-established ERα and ERβ direct tran-
scriptional activities, both ER subtypes are also involved in rapid,
extranuclear, E2 actions in the brain.Membrane initiated estrogen
signaling involves the rapid activation of different protein kinase
pathways, including PKC/PKA/MAPK and PI3K/Akt, to modulate
signal transduction, protein phosphorylation, and gene expression
suitable for cell survival.
Although the speciﬁc role of ERα andERβ in neuroprotection is
openly debated, the studies reviewed here clearly support the idea
that E2 acts as neuroprotective factor through direct and indirect
genomic mechanisms that converge with rapid membrane initi-
ated effects on signaling proteins in order to regulate cell death
and survival factors.
The ﬁeld of E2-induced neuroprotection is booming in recent
years. Formany years ERα has been considered a critical link in the
mechanism of protection of cell death, but the increasing amount
of data propose that also ERβ could play a pivotal role in neuropro-
tection through the integration between the direct genomic and
membrane initiated activities. Thus, a profound knowledge of the
membrane ERβ initiated pathways is required in order to identify
critical players of these mechanisms that might represent target
candidates for therapeutic development in the treatment of post-
menopausal neuronal deﬁciency and neurodegenerative diseases.
Further studies are needed to better characterize the modulation
and themodes of action of Ngb both in in vitro and in vivo models
in order to provide a rational for its pharmacological exploitation
as an effective neuroprotective mediator of E2-dependent actions
in the brain.
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